Enroll your VOXZOGO patients for one-to-one access support

BioMarin RareConnections™ provides families of patients on VOXZOGO with personalized Case Management and has Field Reimbursement Managers available to provide reimbursement education to your clinic, product access education, and logistics support. Learn more about our support services.

VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia who are 5 years of age and older with open growth plates (epiphyses).

Transient decreases in blood pressure were observed in clinical studies. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, fatigue, and/or nausea), patients should be well fed and hydrated in the hour prior to VOXZOGO administration.

To get started, complete both forms below

To be completed by the prescriber:

VOXZOGO Patient Enrollment Form (PEF)

This form serves as the prescription for VOXZOGO.
Download iconDownload the form

To be completed by your patient:

VOXZOGO Patient Consent Form (PCF)

This form grants BioMarin permission to use and disclose the patient’s health information to help them access BioMarin therapies. It must be completed to enroll in BioMarin RareConnections.
Download iconDownload the form
or
Computer iconComplete online with patient
or
Getting patients startedEmail to your patient
VOXZOGO logo VOXZOGO.com/hcp
We’re here to help. For assistance, please call 1-833-VOXZOGO (1-833-869-9649) Monday-Friday, 6AM-5PM PT
BioMarin RareConnections provides one-to-one financial navigation support to help patients start and continue on therapy. Learn more about our services and the following resources:
VOXZOGO Coverage Authorization Guide
A comprehensive resource including sample Letter of Medical Necessity for accessing VOXZOGO treatment for your patients.
VOXZOGO Sample Letter of Medical Necessity
This sample letter can be used as a reference when drafting your letter of medical necessity.
VOXZOGO Patient Support Program for Clinics Flyer
A guide to available BioMarin Patient Support Program services.
VOXZOGO Coverage Authorization Guide
A comprehensive resource including sample Letter of Medical Necessity for accessing VOXZOGO treatment for your patients.
VOXZOGO Patient Support Program for Clinics Flyer
A guide to available BioMarin Patient Support Program services.
BioMarin RareConnections and Specialty Pharmacy Patient Pathway for Clinics Flyer
An outline of the HUB and specialty pharmacy patient pathway.
BioMarin RareConnections and Specialty Pharmacy Patient Pathway for Clinics Flyer
An outline of the HUB and specialty pharmacy patient pathway.
BioMarin RareConnections and Specialty Pharmacy Patient Pathway for Caregivers Flyer
A patient-friendly pathway you can download and provide to your patient’s family.
VOXZOGO Co-Pay Assistance Flyer
A flyer describing the VOXZOGO Co-pay Assistance Program for eligible patients.
BioMarin RareConnections and
Specialty Pharmacy Patient Pathway for Caregivers Flyer
A patient-friendly pathway you can download and provide to your patient’s family.
VOXZOGO Co-Pay Assistance Flyer

A flyer describing the VOXZOGO Co-Pay Assistance Program for eligible patients.

Specialty Pharmacy Contact Sheet
An at-a-glance reference sheet for contacting specialty pharmacies.
Specialty Pharmacy Contact Sheet
An at-a-glance reference sheet for contacting specialty pharmacies.
BioMarin RareConnections and Specialty Pharmacy Patient Pathway for Caregivers Flyer
A patient-friendly pathway you can download and provide to your patient’s family.
VOXZOGO Co-Pay Assistance Flyer
A flyer describing the VOXZOGO Co-pay Assistance Program for eligible patients.

Indication and Important Safety Information

VOXZOGO® (vosoritide) is indicated to increase linear growth in pediatric patients with achondroplasia 5 years of age and older with open growth plates.

  • This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Warnings and Precautions for Risk of Low Blood Pressure

Transient decreases in blood pressure were observed in clinical studies. Patients with significant cardiac or vascular disease and patients on anti-hypertensive medicinal products were excluded from participation in VOXZOGO clinical trials. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, fatigue, and/or nausea), patients should be well hydrated, have adequate food intake, and drink approximately 8-10 ounces of fluid in the hour prior to VOXZOGO administration.

Eight (13%) of 60 patients treated with VOXZOGO had a total of 11 events of transient decrease in blood pressure, compared to 3 (5%) of 61 patients on placebo, over a 52-week treatment period. The median time to onset from injection was 31 (18 to 120) minutes, with resolution within 31 (5 to 90) minutes in VOXZOGO-treated subjects. Two out of 60 (3%) VOXZOGO-treated patients each had one symptomatic episode of decreased blood pressure with vomiting and/or dizziness compared to 0 of 61 (0%) patients on placebo.

Adverse Reactions:

Adverse reactions that occurred in ≥5% of patients treated with VOXZOGO and at a rate greater than that of placebo in the phase 3 study are injection site reactions (including erythema, swelling, urticaria, pain, bruising, pruritus, hemorrhage, discoloration, and induration), vomiting, arthralgia, decrease in blood pressure, gastroenteritis, diarrhea, dizziness, ear pain, influenza, fatigue, seasonal allergy, and dry skin.

Injection site reactions: Injection site reactions occurred in 51 (85%) subjects receiving VOXZOGO and 50 (82%) subjects receiving placebo over a 52-week period of treatment. Patients receiving VOXZOGO experienced a total of 6983 events of injection site reactions, while patients receiving placebo experienced a total of 1776 events of injection site reactions, over a 52-week period, representing 120.4 events per patient/year exposure and 29.2 events per patient/year exposure, respectively. Two patients in the VOXZOGO arm discontinued treatment due to adverse events of pain and anxiety with injections.

Administration and Monitoring:

VOXZOGO is administered as a daily subcutaneous injection. Prior to use, instruct caregivers on proper preparation and administration of VOXZOGO, and ensure caregivers have demonstrated the ability to perform a subcutaneous injection.

Monitor and assess patient body weight, growth, and physical development regularly every 3-6 months. Adjust dosage according to the patient’s actual body weight. Permanently discontinue treatment with VOXZOGO upon confirmation of no further growth potential, indicated by closure of epiphyses.

Special Populations:

  • Safety and effectiveness of VOXZOGO in pediatric patients with achondroplasia below the age of 5 years have not been established.
  • There are no available data on the use of VOXZOGO in pregnant women, or data on the presence of VOXZOGO in human milk, the effects on the breastfed infant, or the effects on milk production.
  • The influence of renal impairment on the pharmacokinetics of VOXZOGO has not been evaluated. No dosage adjustment is needed for patients with eGFR ≥ 60 mL/min/1.73 m2. VOXZOGO is not recommended for patients with eGFR < 60 mL/min/1.73 m2.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to BioMarin at 1-866-906-6100.

Please see additional safety information in the full Prescribing Information.

Indication and Important Safety Information

VOXZOGO® (vosoritide) is indicated to increase linear growth in pediatric patients with achondroplasia 5 years of age and older with open growth plates.

  • This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

Warnings and Precautions for Risk of Low Blood Pressure

Transient decreases in blood pressure were observed in clinical studies. Patients with significant cardiac or vascular disease and patients on anti-hypertensive medicinal products were excluded from participation in VOXZOGO clinical trials. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, fatigue, and/or nausea), patients should be well hydrated, have adequate food intake, and drink approximately 8-10 ounces of fluid in the hour prior to VOXZOGO administration.

Eight (13%) of 60 patients treated with VOXZOGO had a total of 11 events of transient decrease in blood pressure, compared to 3 (5%) of 61 patients on placebo, over a 52-week treatment period. The median time to onset from injection was 31 (18 to 120) minutes, with resolution within 31 (5 to 90) minutes in VOXZOGO-treated subjects. Two out of 60 (3%) VOXZOGO-treated patients each had one symptomatic episode of decreased blood pressure with vomiting and/or dizziness compared to 0 of 61 (0%) patients on placebo.

Adverse Reactions:

Adverse reactions that occurred in ≥5% of patients treated with VOXZOGO and at a rate greater than that of placebo in the phase 3 study are injection site reactions (including erythema, swelling, urticaria, pain, bruising, pruritus, hemorrhage, discoloration, and induration), vomiting, arthralgia, decrease in blood pressure, gastroenteritis, diarrhea, dizziness, ear pain, influenza, fatigue, seasonal allergy, and dry skin.

Injection site reactions: Injection site reactions occurred in 51 (85%) subjects receiving VOXZOGO and 50 (82%) subjects receiving placebo over a 52-week period of treatment. Patients receiving VOXZOGO experienced a total of 6983 events of injection site reactions, while patients receiving placebo experienced a total of 1776 events of injection site reactions, over a 52-week period, representing 120.4 events per patient/year exposure and 29.2 events per patient/year exposure, respectively. Two patients in the VOXZOGO arm discontinued treatment due to adverse events of pain and anxiety with injections.

Administration and Monitoring:

VOXZOGO is administered as a daily subcutaneous injection. Prior to use, instruct caregivers on proper preparation and administration of VOXZOGO, and ensure caregivers have demonstrated the ability to perform a subcutaneous injection.

Monitor and assess patient body weight, growth, and physical development regularly every 3-6 months. Adjust dosage according to the patient’s actual body weight. Permanently discontinue treatment with VOXZOGO upon confirmation of no further growth potential, indicated by closure of epiphyses.

Special Populations:

  • Safety and effectiveness of VOXZOGO in pediatric patients with achondroplasia below the age of 5 years have not been established.
  • There are no available data on the use of VOXZOGO in pregnant women, or data on the presence of VOXZOGO in human milk, the effects on the breastfed infant, or the effects on milk production.
  • The influence of renal impairment on the pharmacokinetics of VOXZOGO has not been evaluated. No dosage adjustment is needed for patients with eGFR ≥ 60 mL/min/1.73 m2. VOXZOGO is not recommended for patients with eGFR < 60 mL/min/1.73 m2.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to BioMarin at 1-866-906-6100.

Please see additional safety information in the full Prescribing Information.